Greater Cannabis Co Inc

What they do

The Company was formed in 2014 and, after a 2018 reverse acquisition of Green C Corporation, shifted to developing cannabinoid therapeutics. Its current focus is a license from Shaare Zedek Scientific Ltd. for a novel cannabinoid therapy targeting autism, schizophrenia, Parkinson's, and Alzheimer's disease, with a joint R&D agreement to continue clinical work. The Company also states it may pursue cannabis-related investments and development opportunities through equity investments, joint ventures, licensing, or acquisitions. It has no products on the market and no revenue.

Revenue drivers

• Cannabinoid therapeutic license — Licensed from Shaare Zedek Scientific Ltd.; currently no sales or commercialization, with milestone payments tied to clinical trials and regulatory approval.
• Prior transmucosal patch platform — Launched an oral transmucosal patch product but only received limited initial orders; management elected to pursue other opportunities, so this is not an ongoing revenue source.
• Other potential cannabis investments — Business plan mentions direct equity investments, joint ventures, or acquisitions, but no specific activities or revenue are disclosed.

Recent performance

For the three months ended March 31, 2026, the Company reported no revenue, net loss of $33,376, and operating cash flow of -$4,376, compared to a net loss of $103,511 and -$11,155 operating cash flow in the same 2025 period. Operating expenses decreased to $33,376 from $43,536 year-over-year. At March 31, 2026, cash was $1,439, total assets $1,439, total liabilities $776,464, and shareholder equity was -$775,025. Annual net losses have been negative each year from 2021 through 2025, with 2025 net loss of $331,612.

Strategy

Management's stated plan is to conduct clinical studies on and commercialize the licensed cannabinoid therapeutic, and to concentrate on cannabis-related investment and development opportunities. The clinical studies are expected to require up to $1,000,000 and up to two years to finalize. The Company is waiting for the Principal Investigator to source specialized active pharmaceutical ingredients (API) needed for a Phase 2 clinical trial, and annual licensing fee payments have been put on hold until that occurs. It has also issued shares and entered into material agreements as part of its financing efforts.

Risks

• Going concern / insufficient capital — Cash of only $1,439 and negative equity of -$775,025 raise substantial doubt about the ability to continue operations.
• No revenue and recurring losses — The Company has had no revenue in recent quarters and has incurred net losses every year from 2021 through 2025.
• Dependence on third-party API sourcing — The Phase 2 trial cannot start until the Principal Investigator sources specialized APIs, with no timeline for when this will occur.
• License and milestone obligations — The license requires escalating annual fees and milestone payments (e.g., $75,000 for Phase 2 initiation) that the Company may not be able to pay given its cash position.

Outlook

Management expects to conduct clinical studies on the licensed therapeutic, but progress is contingent on sourcing APIs and securing additional financing. The annual licensing fee payments are on hold until the API is obtained, and no timeline is provided for that event. The Company plans to pursue cannabis-related investment and development opportunities, but these are not yet defined. Given the minimal cash, future operations depend heavily on raising capital.